Premium
PhRMA White Paper on ADME Pharmacogenomics
Author(s) -
Williams J. Andrew,
Andersson Tommy,
Andersson Tommy B.,
Blanchard Rebecca,
Behm Martin Otto,
Cohen Nadine,
Edeki Timi,
Franc Monique,
Hillgren Kathleen M.,
Johnson Keith J.,
Katz David A.,
Milton Mark N.,
Murray Bernard P.,
Polli Joseph W.,
Ricci Deb,
Shipley Lisa A.,
Vangala Subrahmanyam,
Wrighton Steven A.
Publication year - 2008
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/0091270008319329
Subject(s) - adme , pharmacogenomics , pharmaceutical industry , drug , pharmacology , white paper , risk analysis (engineering) , business , medicine , political science , law
Pharmacogenomic (PGx) research on the absorption, distribution, metabolism, and excretion (ADME) properties of drugs has begun to have impact for both drug development and utilization. To provide a cross‐industry perspective on the utility of ADME PGx, the Pharmaceutical Research and Manufacturers of America (PhRMA) conducted a survey of major pharmaceutical companies on their PGx practices and applications during 2003–2005. This white paper summarizes and interprets the results of the survey, highlights the contributions and applications of PGx by industrial scientists as reflected by original research publications, and discusses changes in drug labels that improve drug utilization by inclusion of PGx information. In addition, the paper includes a brief review on the clinically relevant genetic variants of drug‐metabolizing enzymes and transporters most relevant to the pharmaceutical industry.